Molecule Details
| InChIKey | FLEVIENZILQUKB-XTWQNQIISA-N |
|---|---|
| Canonical SMILES | CCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)nc(C#CC[C@H]4CC[C@H](C(=O)OC)CC4)nc32)[C@H](O)[C@@H]1O |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 3 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.92 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB05009 |
|---|---|
| Drug Name | Apadenoson |
| CAS Number | 250386-15-3 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. It is developed by Bristol-Myers Squibb and is in phase II of clinical trials. |
Categories: Acids, Carbocyclic Adenosine A receptor agonists Adenosine A2 Receptor Agonists Cyclohexanes Cycloparaffins Heterocyclic Compounds, Fused-Ring Hydrocarbons, Acyclic Nucleic Acids, Nucleotides, and Nucleosides Nucleosides Purines
Cross-references: BindingDB: 50364063 CHEMBL1950649 ChemSpider: 28490919 PubChem:9805430 PubChem:175426929
Target Activities (3)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P29274 | ADORA2A | Adenosine receptor A2a | agonist | targets |